

Tumor Volume (mm³)
2400
2200
2000
1800
1600
1400
1200
1000
800
600
400
200
0
10
20
30
40
Day
Carboplatin + Paclitaxel + αPD-L1
Carboplatin + Paclitaxel
Control

Figure 1



Tumor Volume (mm3)
3000
2800
2600
2400
2200
2000
1800
1600
1400
1200
1000
800
600
400
200
0
10
20
30
40
50
Day
Dex
Control
αPD-L1 + Dex
αPD-L1

Figure 2A




Control
Dex
αPD-L1
αPD-L1 + Dex
Tumor Volume (mm³)
Day
4096
2048
1024
512
256
128
64
32
16
8
4
10
20
30
40
50

Figure 2B

Figure 3


OTI transfer
OVA vaccine
+ Dex
Day1
Day 2
Day 4 analysis
Total Spleen OTI CD8+ (x10^6)
*p=0.0002
Total OTI CD8+ (x10^6)
0.20
0.15
0.10
0.05
0.00
DEC-OVA + saline
DEC-OVA + Dex



Tumor volume (mm³)
2000
1500
1000
500
0
0
10
20
30
40
50
60
Day
Control
Carbo/Abx
Anti-PD-L1
(10% PR)
Anti-PD-L1/Carbo/Abx
(50% CR)
> 90 days

Figure 4A



control
α-PD-L1
Carbo/Abx
αPD-L1/Carbo/Abx
Tumor Volume (mm³)
Day
4096
2048
1024
512
256
128
64
32
16
20
40
60
80
100
1
2
3
5

Figure 4B



% total CD4+ and CD8+ T cells
%
25
20
15
10
5
0
CD4+
CD8+
% IFNγ+ T cells
% IFNγ+
50
40
30
20
10
0
p=0.011
p=0.019
CD4+
CD8+
Primary challenge
Secondary challenge

Figure 5A

Figure 5B



Primary challenge
Secondary challenge
4.96
15.2
19.2
35.6
CD4
CD8
IFNγ
0
100
1000
10000
1x10 5

Figure 6A



MPDL3280A/ABRAXANE®/carboplatin
SD (n=4)
CR/PR (n=9)
PD (n=1)
Discontinued
New Lesion
Change in Sum of Longest Diameters from Baseline (%)
Time on Study (Days)
100
90
80
70
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
-60
-70
-80
-90
-100
0
42
84
126
168
210
252
294

Figure 6B

MPDL3280A/paclitaxel/carboplatin

